HER2 (in the TACT and TEAM trials) differentially affects invasive potential in ER-ve and ER+ve breast cancers

Authors :: Jms Bartlett
D.W. Rea
Margaret Grant
Peter Barrett-Lee
L. Johnson
David Cameron
Elizabeth Mallon
S.R.D. Johnston
Emma Hall
A. Forsyth
Source :: Journal of Clinical Oncology. 23:9557-9557
Publication Year :: 2005
Publisher :: American Society of Clinical Oncology (ASCO), 2005.
Abstract: 9557 Background: HER2 status varies within different breast cancer populations and is inversely related to ER expression. Recent data, from the TACT trial, suggested that HER2 positivity in ER+ve d...

Subjects :: Oncology
Gynecology
Cancer Research
medicine.medical_specialty
business.industry
Tact
medicine.disease
Breast cancer
Internal medicine
Medicine
skin and connective tissue diseases
business
neoplasms

Full Text Access

Tools